Product Description
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Nondrug
Route of Administration: Subcutaneous,Topical,Nasal
FDA Designation: Orphan Drug - Keratitis *
Approval Status: Not Approved
Approved Countries: New Zealand | Slovenia | South Africa | Switzerland | United Arab Emirates | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Johannes Lauscher
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic:
Active Clinical Trial Count: 1
Highest Development Phases
Phase 3: Surgical Wound Infection
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2017-000152-26 | P3 |
Completed |
Surgical Wound Infection |
2022-07-27 |